Low-grade gliomas: an update on pathology and therapy (Q30438449)

21 June 2017

1 reference

title

Low-grade gliomas: an update on pathology and therapy (English)

1 reference

21 June 2017

0 references

Robert Cavaliere

1

1 reference

PubMed ID

16239183

21 June 2017

Maria Beatriz S Lopes

series ordinal

2

1 reference

PubMed ID

16239183

21 June 2017

David Schiff

series ordinal

3

1 reference

21 June 2017

1 November 2005

1 reference

21 June 2017

1 reference

21 June 2017

4

1 reference

21 June 2017

11

1 reference

21 June 2017

760-770

1 reference

Pathology of low-grade gliomas: an update of emerging concepts

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Preferential brain locations of low-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Epidemiology of primary brain tumors: current concepts and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

MRI in treatment of adult gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group stud

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Long-term outcome of low-grade oligodendroglioma and mixed glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Cellular proliferation in pilocytic and diffuse astrocytomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

The prognostic significance of Ki-67 labeling indices for oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Gemistocytic astrocytomas: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

p14ARF deletion and methylation in genetic pathways to glioblastomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Sonic hedgehog--regulated oligodendrocyte lineage genes encoding bHLH proteins in the mammalian central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Identification of a novel family of oligodendrocyte lineage-specific basic helix-loop-helix transcription factors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

OLIG-1 and 2 gene expression and oligodendroglial tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

OLIG2 as a specific marker of oligodendroglial tumour cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Molecular genetic evidence for subtypes of oligoastrocytomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Genetic modeling of glioma formation in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Low-grade pure and mixed cerebral astrocytomas treated in the CT scan era.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Age-dependent rate of anaplastic transformation in low-grade astrocytoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Low-grade glial tumors in basal ganglia and thalamus: natural history and biological reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Proliferation index is related to patient age in glioblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Somatic mutations in the brain: relationship to aging?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

5-year survival and clinical prognostic factors in progressive supratentorial diffuse "low-grade" astrocytoma: a retrospective analysis of 46 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Seizures in patients with supratentorial oligodendroglial tumours. Clinicopathological features and management considerations.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Prevalence and prognostic significance of epilepsy in patients with gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

The prognosis of primary intracerebral tumours presenting with epilepsy: the outcome of medical and surgical management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Low-grade gliomas of chronic epilepsy: a distinct clinical and pathological entity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Low-grade astrocytomas may arise from different astrocyte lineages.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Coexistence of neoplasia and cortical dysplasia in patients presenting with seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

MIB-1 proliferation index predicts survival among patients with grade II astrocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Supratentorial low-grade glioma: results and prognostic factors following postoperative radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Supratentorial low-grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Suspected low-grade glioma: is deferring treatment safe?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Radiation therapy for incompletely resected supratentorial low-grade glioma in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Radiation therapy in the treatment of cerebral astrocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Early vs. delayed radiotherapy in a small cohort of patients with supratentorial low grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Radiotherapy for malignant glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Dementia following treatment of brain tumors with radiotherapy administered alone or in combination with nitrosourea-based chemotherapy: a clinical and pathological study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Radiation response of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Methylphenidate therapy improves cognition, mood, and function of brain tumor patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Subacute brain atrophy after radiation therapy for malignant brain tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Delayed radiation toxicity after focal or whole brain radiotherapy for low-grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Neurological complications of radiotherapy and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Late cognitive and radiographic changes related to radiotherapy: initial prospective findings

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Supratentorial low-grade astrocytomas in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Radiation therapy in the management of low-grade supratentorial astrocytomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

The value of radiation therapy in addition to surgery for astrocytomas of the adult cerebrum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Management of oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Successful chemotherapy for recurrent malignant oligodendroglioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Phase II trial of temozolomide in patients with progressive low-grade glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Low-grade oligodendroglioma responds to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Temozolomide: a novel oral alkylating agent

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

Inhibition of angiogenesis by non-toxic doses of temozolomide

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970222-2

7 January 2021

10.1016/S1474-4422(05)70222-2

Identifiers

DOI

1 reference

21 June 2017

1 reference

PubMed ID

16239183